Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02287428
Title Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma

giant cell glioblastoma

gliosarcoma

Therapies

NeoVax

Pembrolizumab

Temozolomide

NeoVax + Pembrolizumab + Temozolomide

NeoVax + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.